Trial reportPloS one2025
VIVALDI-CT shaping care home COVID-19 testing policy: A pragmatic cluster randomised controlled trial of asymptomatic testing compared to standard care in care home staff.
Trial report in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05639205 (Shaping Care Home COVID-19 Testing Policy), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Shaping Care Home COVID-19 Testing Policy: A Pragmatic Cluster Randomised Controlled Trial of Asymptomatic Testing Compared to Standard Care in Care Home Staff.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNon-pharmaceutical interventions were used widely in care homes for older people during the COVID-19 pandemic, but there have been few randomised trials to support policy decisions. We aimed to evaluate the effect of biweekly asymptomatic staff testing with support funding for sick pay and agency staffing on the clinical outcomes of residents.
methodsWe conducted a cluster randomised unblinded superiority trial, aiming to recruit up to 280 residential and/or nursing homes in England providing care to adults aged >65 years. Homes were randomised 1:1 to the control arm, which followed national testing policy (comprising symptomatic plus outbreak testing at trial initiation) or intervention (additional twice weekly asymptomatic staff testing for SARS-CoV-2, staff sick pay and agency backfill). Outcomes were evaluated using health data from routine national datasets in combination with aggregate data from participating homes. The primary outcome was the incidence of COVID-19-related hospital admissions in residents.
resultsThe trial was conducted from January to August 2023, with 41 care homes randomised to intervention and 40 randomised to control included in the analysis. The trial was stopped early as it was not adequately powered for the primary outcome due to site recruitment and primary outcome events being substantially lower than expected. There was no significant difference in the primary outcome of resident COVID-linked hospital admission incidence between intervention and control arms (22.7/1000 person-years vs 15.0/1000 person-years, incidence rate ratio 1.19, 95%CI 0.55-2.58, P = 0.66; incidence rate difference 4.0, 95%CI -14.3 to 22.2). Trial set up took less than three months. Most trial outcomes were derived from routinely collected data. Recorded uptake of staff testing in the intervention arm was low (mean per home each week 14.4%).
conclusionThis trial was not well-powered to evaluate the impact of the intervention on the primary outcome, and recorded uptake of staff testing was low. However, our pre-existing care home network underpinned by linked routinely collected data provides a model for more agile interventional studies in the care home setting. CLINICALTRIALS.GOV REGISTRATION: NCT05639205.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.